Antares Pharma, Inc. ATRS
Set alert
5.59 +5.59 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 25.41
- Beta
- 1.15
- Short ratio
- 0.41
- Inst. own
- 62.83%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 10, 2022
- 50-d avg
- 4.90
- 200-d avg
- 3.92
- 1y target
- 5.95
Analyst view
Consensus: hold
Hold
Price target (mean) 5.95 +6.4% upside
Now 5.59
- Target (low)
- 5.60
- Target (mean)
- 5.95
- Target (high)
- 7.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 6
- 2 months ago 6
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.01 | 0.00 – 0.02 | 0.03 | -66.7% | 49.79M | 0.0% | 4 |
| Next quarter | 0.03 | 0.01 – 0.06 | 0.03 | 0.0% | 57.20M | +18.7% | 4 |
| Current year | 0.08 | 0.06 – 0.11 | 0.26 | -69.2% | 210.84M | +14.6% | 4 |
| Next year | 0.22 | 0.19 – 0.27 | 0.08 | +175.0% | 261.04M | +23.8% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 14, 2022 | Truist Securities | Downgrade | Buy | Hold |
| Apr 14, 2022 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Apr 14, 2022 | Raymond James | Downgrade | Strong Buy | Market Perform |
| Apr 14, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 14, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Nov 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 16, 2021 | Truist Securities | Initiated | — | Buy |
| May 10, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| May 6, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 4, 2020 | Raymond James | Maintained | — | Strong Buy |
| Mar 4, 2019 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Oct 2, 2018 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Jun 23, 2017 | Chardan Capital | Initiated | — | Buy |
| Apr 21, 2017 | Raymond James | Initiated | — | Strong Buy |
| Mar 9, 2016 | Jefferies | Maintained | — | Buy |
| May 28, 2015 | Jefferies | Initiated | — | Buy |
| May 18, 2015 | PiperJaffray | Initiated | — | Overweight |
| Oct 22, 2014 | JMP Securities | Initiated | — | Outperform |
| May 12, 2014 | Oppenheimer | Maintained | — | Outperform |
| Oct 8, 2013 | Jefferies | Maintained | — | Buy |
| Dec 19, 2012 | Jefferies | Initiated | — | Buy |
| Nov 26, 2012 | Guggenheim | Initiated | — | Buy |
| Aug 8, 2012 | Oppenheimer | Maintained | — | Outperform |